XML 87 R75.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 56 Months Ended
Jan. 31, 2019
Sep. 30, 2018
Feb. 28, 2017
Jan. 31, 2017
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jan. 01, 2019
Dec. 31, 2018
Nov. 30, 2014
Commitments                      
Operating lease, liability         $ 7,393 $ 7,393   $ 7,393      
Operating lease, right-of-use asset         $ 6,582 $ 6,582   $ 6,582      
Weighted average remaining operating lease term         2 years 1 month 6 days 2 years 1 month 6 days   2 years 1 month 6 days      
Weighted average operating lease discount rate         4.63% 4.63%   4.63%      
Lease cost         $ 1,400 $ 2,500          
Operating cash outflows from operating leases           2,700          
Right-of-use asset obtained in exchange for lease obligations           1,000          
Minimum purchase commitments         50,800 50,800   $ 50,800      
Contingent consideration paid           27 $ 60        
Milestone payment accrued for FDA approval of Vyleesi         60,000 60,000   60,000   $ 0  
Velo Bio, LLC | Regulatory Milestone Achievement                      
Commitments                      
Milestone payments   $ 5,000                  
Velo Bio, LLC | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval                      
Commitments                      
Milestone payments   30,000                  
Velo Bio, LLC | Annual Sales Milestone Achievements                      
Commitments                      
Milestone payments   240,000                  
Velo Bio, LLC | Commercial Milestone Payments                      
Commitments                      
Milestone payments   10,000                  
Endoceutics, Inc. | Intrarosa | First Sales Milestone Achievement                      
Commitments                      
Potential milestone payment, triggering event, sales     $ 150,000                
Future contingent payments (up to)     15,000                
Endoceutics, Inc. | Intrarosa | Second Sales Milestone Achievement                      
Commitments                      
Potential milestone payment, triggering event, sales     300,000                
Future contingent payments (up to)     30,000                
Endoceutics, Inc. | Intrarosa | Third Sales Milestone Achievement                      
Commitments                      
Potential milestone payment, triggering event, sales     500,000                
Future contingent payments (up to)     850,000                
Endoceutics, Inc. | Intrarosa | Tiered Royalties                      
Commitments                      
Potential milestone payment, triggering event, sales     $ 150,000                
Royalty percentage, maximum     25.00%                
Net sales threshold, future contingent payments     $ 1,000,000                
Period after first commercial sale     10 years                
Palatin Technologies, Inc. | Vyleesi Products | First Sales Milestone Achievement                      
Commitments                      
Potential milestone payment, triggering event, sales       $ 250,000              
Future contingent payments (up to)       25,000              
Palatin Technologies, Inc. | Vyleesi Products | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval                      
Commitments                      
Future contingent payments (up to)       $ 60,000              
Milestone payment accrued for FDA approval of Vyleesi         60,000 $ 60,000   60,000      
Palatin Technologies, Inc. | Vyleesi Products | Tiered Royalties                      
Commitments                      
Period after first commercial sale       10 years              
Palatin Technologies, Inc. | Vyleesi Products | Achievement of Certain Annual Sales Milestones over Course of License Agreement                      
Commitments                      
Future contingent payments (up to)       $ 300,000              
Minimum                      
Commitments                      
Remaining operating lease term           1 year          
Minimum | Velo Bio, LLC | Annual Sales Milestone Achievements                      
Commitments                      
Sales milestone targets   300,000                  
Maximum                      
Commitments                      
Remaining operating lease term           4 years          
Maximum | Velo Bio, LLC | Annual Sales Milestone Achievements                      
Commitments                      
Sales milestone targets   $ 900,000                  
Lumara Health Inc.                      
Commitments                      
Contingent consideration (up to)                     $ 350,000
Business acquisition, contingent consideration, liability             $ 50,000        
Lumara Health Inc. | Annual Net Sales Milestone                      
Commitments                      
Contingent consideration paid               150,000      
Accounting Standards Update 2016-02                      
Commitments                      
Operating lease, liability         7,400 $ 7,400   7,400 $ 8,500    
Operating lease, right-of-use asset         $ 6,600 $ 6,600   $ 6,600 $ 7,600    
Perosphere Pharmaceuticals Inc.                      
Commitments                      
Contingent consideration (up to) $ 365,000                    
Perosphere Pharmaceuticals Inc. | Regulatory Milestone Achievement                      
Commitments                      
Contingent consideration (up to) $ 140,000                    
Credited percentage 50.00%                    
Perosphere Pharmaceuticals Inc. | Milestone Achievement, Approval By European Medicines Agency                      
Commitments                      
Contingent consideration (up to) $ 40,000                    
Perosphere Pharmaceuticals Inc. | Sales Milestones Achievement                      
Commitments                      
Contingent consideration (up to) 225,000                    
Perosphere Pharmaceuticals Inc. | First Sales Milestone Achievement                      
Commitments                      
Contingent consideration, milestone payment 20,000                    
Potential milestone payment, triggering event, sales $ 100,000